Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab

Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • ADP-ribosyl Cyclase 1 / biosynthesis*
  • ADP-ribosyl Cyclase 1 / genetics
  • Antibodies, Monoclonal / pharmacology*
  • Antigens, Neoplasm / biosynthesis*
  • Antigens, Neoplasm / genetics
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic / drug effects*
  • Histone Deacetylase Inhibitors / administration & dosage
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Hydroxamic Acids / administration & dosage
  • Hydroxamic Acids / pharmacology*
  • Indoles / administration & dosage
  • Indoles / pharmacology*
  • Membrane Glycoproteins / biosynthesis*
  • Membrane Glycoproteins / genetics
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics
  • Panobinostat
  • Signaling Lymphocytic Activation Molecule Family / biosynthesis
  • Signaling Lymphocytic Activation Molecule Family / genetics
  • Tumor Cells, Cultured
  • Up-Regulation / drug effects

Substances

  • Antibodies, Monoclonal
  • Antigens, Neoplasm
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Membrane Glycoproteins
  • Neoplasm Proteins
  • SLAMF7 protein, human
  • Signaling Lymphocytic Activation Molecule Family
  • daratumumab
  • Panobinostat
  • CD38 protein, human
  • ADP-ribosyl Cyclase 1